Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1821

Shown on this page

Current sort

Live official records

Conditions: Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Interventions: LY4152199 - IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more

Conditions: Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions: PF-08634404, Bevacizumab, Chemotherapy; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 254
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more

Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 334
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more

Conditions: AL Amyloidosis
Interventions: Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more

Conditions: Lung Transplant
Interventions: Tocilizumab, Placebo for Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 54
States / cities: Mesa, Arizona • Sun City, Arizona • Campbell, California + 50 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 76
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more

Conditions: Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions: LY4268989, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 52
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 46 more

Conditions: Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Interventions: Donanemab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 68 more

Conditions: Breast Neoplasms
Interventions: Imlunestrant, Goserelin, Tamoxifen 20 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 34
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more

Conditions: Ventricular Arrhythmia, Tachycardia
Interventions: Defibrillation using EV-ICD; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 57
States / cities: Huntington Park, California • Redwood City, California • San Diego, California + 45 more

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Tocilizumab in Lung Transplantation

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Enlighten Study: The EV-ICD Post Approval Registry

About this Mayo Clinic institution page